Clinical Cancer Research Prevention Award Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shibahara, K.
Right arrow Articles by Kuwano, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shibahara, K.
Right arrow Articles by Kuwano, M.
Clinical Cancer Research Vol. 7, 3151-3155, October 2001
© 2001 American Association for Cancer Research

Regular Articles

Nuclear Expression of the Y-Box Binding Protein, YB-1, as a Novel Marker of Disease Progression in Non-Small Cell Lung Cancer1

Kotaro Shibahara, Kenji Sugio, Toshihiro Osaki, Takeshi Uchiumi, Yoshihiko Maehara, Kimitoshi Kohno, Kosei Yasumoto, Keizo Sugimachi and Michihiko Kuwano2

Departments of Medical Biochemistry [Ko. S., T. U., M. K.] and Surgery and Science [Y. M., Kei. S.], Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, and Departments of Surgery II [Ken. S., T. O., K. Y.] and Molecular Biology [K. K.], University of Occupational and Environmental Health, Yahatanishi-ku, Kitakyushu 807-8555, Japan

Transcription factor Y-box binding protein 1 (YB-1) that binds to the nverted CCAAT box is involved not only in transcription of various genes but also in cell proliferation and DNA repair. We determined whether localization of YB-1 in either the nucleus or cytoplasm could serve as a prognostic marker for patients with non-small cell lung cancer (NSCLC). In 196 NSCLC patients, expression of YB-1 protein in the nucleus or cytoplasm was immunohistochemically evaluated. Of the 196 tumors examined, 88 (44.9%) were positive for YB-1 expression in the nucleus. Nuclear YB-1 expression significantly correlated with T factor, lymph node metastasis, and stage of the disease. Patients with a nuclear YB-1 tumor had a poorer prognosis than did those with a cytoplasmic YB-1 tumor in all of the NSCLC patients (P = 0.0494) and in patients with squamous cell carcinoma (P = 0.0313) but not in patients with adenocarcinomas. Nuclear localization of the YB-1 protein may prove to be an important factor of disease progression for patients with NSCLC, in particular, in cases of squamous cell carcinoma.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
T. Fujii, A. Kawahara, Y. Basaki, S. Hattori, K. Nakashima, K. Nakano, K. Shirouzu, K. Kohno, T. Yanagawa, H. Yamana, et al.
Expression of HER2 and Estrogen Receptor {alpha} Depends upon Nuclear Localization of Y-Box Binding Protein-1 in Human Breast Cancers
Cancer Res., March 1, 2008; 68(5): 1504 - 1512.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. M. Paranjape and E. Harris
Y Box-binding Protein-1 Binds to the Dengue Virus 3'-Untranslated Region and Mediates Antiviral Effects
J. Biol. Chem., October 19, 2007; 282(42): 30497 - 30508.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
K. To, Y. Zhao, H. Jiang, K. Hu, M. Wang, J. Wu, C. Lee, D. W. Yokom, A. L. Stratford, U. Klinge, et al.
The Phosphoinositide-Dependent Kinase-1 Inhibitor 2-Amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) Prevents Y-Box Binding Protein-1 from Inducing Epidermal Growth Factor Receptor
Mol. Pharmacol., September 1, 2007; 72(3): 641 - 652.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Mantwill, N. Kohler-Vargas, A. Bernshausen, A. Bieler, H. Lage, A. Kaszubiak, P. Surowiak, T. Dravits, U. Treiber, R. Hartung, et al.
Inhibition of the Multidrug-Resistant Phenotype by Targeting YB-1 with a Conditionally Oncolytic Adenovirus: Implications for Combinatorial Treatment Regimen with Chemotherapeutic Agents.
Cancer Res., July 15, 2006; 66(14): 7195 - 7202.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Wu, C. Lee, D. Yokom, H. Jiang, M. C.U. Cheang, E. Yorida, D. Turbin, I. M. Berquin, P. R. Mertens, T. Iftner, et al.
Disruption of the Y-Box Binding Protein-1 Results in Suppression of the Epidermal Growth Factor Receptor and HER-2.
Cancer Res., May 1, 2006; 66(9): 4872 - 4879.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
G. Glockzin, K. Mantwill, K. Jurchott, A. Bernshausen, A. Ladhoff, H.-D. Royer, B. Gansbacher, and P. S. Holm
Characterization of the Recombinant Adenovirus Vector AdYB-1: Implications for Oncolytic Vector Development.
J. Virol., April 1, 2006; 80(8): 3904 - 3911.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Yasen, K. Kajino, S. Kano, H. Tobita, J. Yamamoto, T. Uchiumi, S. Kon, M. Maeda, G. Obulhasim, S. Arii, et al.
The Up-Regulation of Y-Box Binding Proteins (DNA Binding Protein A and Y-Box Binding Protein-1) as Prognostic Markers of Hepatocellular Carcinoma
Clin. Cancer Res., October 15, 2005; 11(20): 7354 - 7361.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
C. R.C. van Roeyen, F. Eitner, S. Martinkus, S. R. Thieltges, T. Ostendorf, D. Bokemeyer, B. Luscher, J. M. Luscher-Firzlaff, J. Floege, and P. R. Mertens
Y-Box Protein 1 Mediates PDGF-B Effects in Mesangioproliferative Glomerular Disease
J. Am. Soc. Nephrol., October 1, 2005; 16(10): 2985 - 2996.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
A. G. Bader and P. K. Vogt
Inhibition of Protein Synthesis by Y Box-Binding Protein 1 Blocks Oncogenic Cell Transformation
Mol. Cell. Biol., March 15, 2005; 25(6): 2095 - 2106.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Uramoto, K. Sugio, T. Oyama, S. Nakata, K. Ono, M. Morita, K. Funa, and K. Yasumoto
Expression of {Delta}Np73 Predicts Poor Prognosis in Lung Cancer
Clin. Cancer Res., October 15, 2004; 10(20): 6905 - 6911.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
C. Gessner, C. Woischwill, A. Schumacher, U. Liebers, H. Kuhn, P. Stiehl, K. Jurchott, H.D. Royer, C. Witt, and G. Wolff
Nuclear YB-1 expression as a negative prognostic marker in nonsmall cell lung cancer
Eur. Respir. J., January 1, 2004; 23(1): 14 - 19.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. S. Holm, H. Lage, S. Bergmann, K. Jurchott, G. Glockzin, A. Bernshausen, K. Mantwill, A. Ladhoff, A. Wichert, J. S. Mymryk, et al.
Multidrug-resistant Cancer Cells Facilitate E1-independent Adenoviral Replication: Impact for Cancer Gene Therapy
Cancer Res., January 1, 2004; 64(1): 322 - 328.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. G. Bader, K. A. Felts, N. Jiang, H. W. Chang, and P. K. Vogt
Y box-binding protein 1 induces resistance to oncogenic transformation by the phosphatidylinositol 3-kinase pathway
PNAS, October 14, 2003; 100(21): 12384 - 12389.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Lasham, S. Moloney, T. Hale, C. Homer, Y. F. Zhang, J. G. Murison, A. W. Braithwaite, and J. Watson
The Y-box-binding Protein, YB1, Is a Potential Negative Regulator of the p53 Tumor Suppressor
J. Biol. Chem., September 12, 2003; 278(37): 35516 - 35523.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Jurchott, S. Bergmann, U. Stein, W. Walther, M. Janz, I. Manni, G. Piaggio, E. Fietze, M. Dietel, and H.-D. Royer
YB-1 as a Cell Cycle-regulated Transcription Factor Facilitating Cyclin A and Cyclin B1 Gene Expression
J. Biol. Chem., July 18, 2003; 278(30): 27988 - 27996.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
F. Meric and K. K. Hunt
Translation Initiation in Cancer: A Novel Target for Therapy
Mol. Cancer Ther., September 1, 2002; 1(11): 971 - 979.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.